Amalgamated Bank lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 7.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,980 shares of the biopharmaceutical company’s stock after acquiring an additional 352 shares during the period. Amalgamated Bank’s holdings in Ultragenyx Pharmaceutical were worth $309,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Sei Investments Co. bought a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $125,000. Pacer Advisors Inc. increased its position in shares of Ultragenyx Pharmaceutical by 22.6% during the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 560 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.7% during the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 115 shares in the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 250 shares in the last quarter. Finally, Karp Capital Management Corp bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $241,000. 96.07% of the stock is owned by institutional investors.

RARE has been the subject of several research reports. Canaccord Genuity set a $98.00 price objective on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, July 28th. Stifel Nicolaus reissued a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. J P Morgan Chase & Co set a $76.00 price objective on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, August 23rd. Finally, Robert W. Baird reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $71.94.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis purchased 7,500 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was acquired at an average price of $52.52 per share, for a total transaction of $393,900.00. Following the purchase, the chief executive officer now owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amalgamated Bank Raises Stake in Ultragenyx Pharmaceutical Inc. (RARE)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/amalgamated-bank-raises-stake-in-ultragenyx-pharmaceutical-inc-rare/1622876.html.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) opened at 54.01 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $49.56 and a 52 week high of $91.35. The firm has a 50-day moving average of $53.50 and a 200-day moving average of $59.83. The firm’s market cap is $2.29 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. During the same quarter in the prior year, the business posted ($1.46) EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.14) EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.